Table 6 Toxicity of the clinical trials with doxorubicin

Banerjee et al. (2018)

ROC

PLD

6

2

6

6

Lee et al. (2017)

ROC

PLD

3

Monk et al. (2017)^a

ROC

PLD

74.1

33.3

4.1

Marth et al. (2017)

ROC

PLD

5

5

5

6

6

2

Lindemann et al. (2017)

ROC

PLD

2

7

7

Herzog et al. (2016)

ROC

PLD

Runnebaum et al. (2018)

ROC

PLD + trebananib

10

5

5

Lee et al. (2017)

ROC

PLD + carboplatin

13

Sehouli et al. (2016)

ROC

PLD + carboplatin

15

2

2

Nagao et al. (2016)

ROC

PLD + paclitaxel + carboplatin

33

17

50

Landrum et al. (2016)

ROC

PLD + carboplatin + bevacizumab + veliparib

40

Kim et al. (2015)

ROC

PLD + carboplatin + farletuzumab

67

33

20

20

33

Monk et al. (2017)^a

ROC

PLD + motolimod

87.8

50.3

10.9

Marth et al. (2017)

ROC

PLD + trebananib

7

6

3

6

7

2

Shoji et al. (2017)

ROC

PLD + irinotecan

3

3

3

3

10

Thaker et al. (2017)

ROC

PLD + GEN

28

Herzog et al. (2016)

ROC

PLD + vintafolide

5

Jehn et al. (2016)

MBC

Caelix^®

Harbeck et al. (2016)

MBC

PLD

1

4

6

Chang et al. (2018)

MBC

PLD + cyclophosphamide

10

5

1

Tampaki et al. (2018)

BC

PLD + cyclophosphamide + bevacizumab + paclitaxel

1.6

6.5

1.6

9.7

Basho et al. (2016)

TNBC

PLD + bevacizumab + temsirolimus

4

4

8

PLD + bevacizumab + everolimus

11

22

11

Rocca et al. (2017)

BC

PLD + lapatinib

11

11

Coltelli et al. (2017)

BC

Myocet^® + cyclophosphamide + PTX

6

4

6

Cohen et al. (2018)

MM

PLD + pomalidomide + dexamethasone

4

9

Orlowski et al. (2016)

RMM

PLD + bortezomib

Becker et al. (2016)

MM

PLD + bortezomib + cyclophosphamide + dexamethasone

5

5

Voorhees et al. (2017)

RMM

PLD + bortezomib + vorinostat

47

16

9

19

9

Luminari et al. (2017)

DLBCL

Myocet^® + cyclophosphamide + vincristine + prednisone

8

2

Fridrik et al. (2016)

DLBCL

Myocet^® + cyclophosphamide + vincristine + prednisone + rituximab

29